2023
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuita L, Bonzheim I, Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine 2023, 93: 104644. PMID: 37295047, PMCID: PMC10363450, DOI: 10.1016/j.ebiom.2023.104644.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesMultiple Cox regressionMelanoma-specific survivalCox regressionTumor thicknessCutaneous melanomaPrimary melanomaAssessment of TILsPD-1 checkpoint inhibitionSignificant unfavourable prognostic factorLonger progression-free survivalDistant metastasis-free survivalSimple Cox regressionUnfavourable survival outcomeFirst-line therapyProgression-free survivalUnfavourable prognostic factorCutaneous melanoma patientsMetastasis-free survivalPresence of ulcerationPrimary cutaneous melanomaCox regression modelPrimary melanoma samplesPrimary tissuesOverall survival
2022
Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma.
Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Psyrri A, Rimm D. Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2022, 40: 6050-6050. DOI: 10.1200/jco.2022.40.16_suppl.6050.Peer-Reviewed Original ResearchNeck squamous cell carcinomaM HNSCC patientsSquamous cell carcinomaB2M expressionOverall survivalHNSCC patientsValidation cohortCell carcinomaB2MPre-treatment biopsy samplesUnivariate Cox regression modelM expressionFunctional antigen presentationHigh beta2-microglobulinTreatment of recurrentImmune checkpoint expressionCox regression modelImmune cell markersStandard of careIndependent validation cohortSpatial profiling technologyDigital spatial profilingDigital spatial profiling (DSP) technologyImmune stromaM HNSCC
2014
In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A. In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. PLOS ONE 2014, 9: e99131. PMID: 24968015, PMCID: PMC4072595, DOI: 10.1371/journal.pone.0099131.Peer-Reviewed Original ResearchConceptsBreast cancer patientsMetastatic breast cancer patientsFISH HER2Cancer patientsHER2 mRNAPrognostic factorsTrastuzumab-treated metastatic breast cancer patientsMultivariate Cox regression modelECD HER2Log rank pMetastatic breast cancerStrong prognostic factorCox regression modelKaplan-Meier estimatesHER2 mRNA levelsHER2-ICDChemotherapy regimensMetastatic cohortTrastuzumab treatmentBreast cancerTissue microarrayMRNA statusPerformance of markersHER2 receptorPredictive value
2010
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
Parisi F, González A, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Research 2010, 12: r66. PMID: 20809974, PMCID: PMC3096952, DOI: 10.1186/bcr2633.Peer-Reviewed Original ResearchConceptsNottingham Prognostic IndexClinico-pathological variablesPrognostic indexCox modelPrognostic modelMultivariate Cox regression modelEarly-stage breast cancerBreast cancer patient cohortsAdjuvant chemotherapy decisionsMultivariate Cox modelStage breast cancerCox regression modelCancer patient cohortsTime-dependent areaBreast cancer prognostic modelsCancer prognostic modelsNPI groupOncotype DXPatient cohortChemotherapy decisionsPrognostic markerBackward selection procedureBreast cancerQuantitative immunofluorescence methodImmunofluorescence method
2009
Predictive value of p27 for the benefit of adjuvant anthracycline-based chemotherapy in early breast cancer.
Conforti R, Moeder C, Tomasic G, Boulet T, Nahta R, Yuan L, Spielmann M, Delaloge S, Michiels S, Rimm D, Esteva F, Andre F. Predictive value of p27 for the benefit of adjuvant anthracycline-based chemotherapy in early breast cancer. Cancer Research 2009, 69: 6063. DOI: 10.1158/0008-5472.sabcs-6063.Peer-Reviewed Original ResearchEarly breast cancerHazard ratioInstitut Gustave RoussyPredictive valueOverall survivalControl armBreast cancerAdjuvant anthracycline-based chemotherapyHR of deathCytoplasmic expressionTumor samplesAdjusted hazard ratioAnthracycline-based chemotherapyDisease-free survivalBreast cancer patientsCox regression modelInteraction p valueUnit increaseAdjuvant anthracyclinesAdjuvant treatmentCyclin-dependent kinase inhibitorEGFR tumorsER expressionRandomized trialsPredictive factors